ImmuPharma End Period Cash Flow vs Net Income Analysis

IMM Stock   1.43  0.04  2.72%   
ImmuPharma PLC financial indicator trend analysis is infinitely more than just investigating ImmuPharma PLC recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether ImmuPharma PLC is a good investment. Please check the relationship between ImmuPharma PLC End Period Cash Flow and its Net Income accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in ImmuPharma PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

End Period Cash Flow vs Net Income

End Period Cash Flow vs Net Income Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of ImmuPharma PLC End Period Cash Flow account and Net Income. At this time, the significance of the direction appears to have weak contrarian relationship.
The correlation between ImmuPharma PLC's End Period Cash Flow and Net Income is -0.03. Overlapping area represents the amount of variation of End Period Cash Flow that can explain the historical movement of Net Income in the same time period over historical financial statements of ImmuPharma PLC, assuming nothing else is changed. The correlation between historical values of ImmuPharma PLC's End Period Cash Flow and Net Income is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which End Period Cash Flow of ImmuPharma PLC are associated (or correlated) with its Net Income. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Income has no effect on the direction of End Period Cash Flow i.e., ImmuPharma PLC's End Period Cash Flow and Net Income go up and down completely randomly.

Correlation Coefficient

-0.03
Relationship DirectionNegative 
Relationship StrengthInsignificant

End Period Cash Flow

Net Income

Net income is one of the most important fundamental items in finance. It plays a large role in ImmuPharma PLC financial statement analysis. It represents the amount of money remaining after all of ImmuPharma PLC operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.
Most indicators from ImmuPharma PLC's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into ImmuPharma PLC current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in ImmuPharma PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
The current year's Selling General Administrative is expected to grow to about 1.7 M, whereas Tax Provision is forecasted to decline to (522 K).
 2021 2022 2023 2024 (projected)
Interest Expense2.4M1.5M2.0K1.9K
Depreciation And Amortization114.1K117.6K37.6K35.7K

ImmuPharma PLC fundamental ratios Correlations

-0.160.030.99-0.930.350.920.17-0.470.590.92-0.19-0.320.07-0.220.370.96-0.210.650.11-0.430.22-0.130.40.16-0.19
-0.160.5-0.250.11-0.32-0.1-0.21-0.15-0.12-0.10.440.57-0.040.250.57-0.130.41-0.04-0.220.05-0.01-0.15-0.38-0.230.41
0.030.5-0.080.12-0.65-0.120.220.170.12-0.120.740.730.240.590.76-0.080.75-0.180.470.330.110.53-0.25-0.710.74
0.99-0.25-0.08-0.920.380.910.21-0.460.560.91-0.24-0.370.05-0.230.240.95-0.260.620.1-0.470.2-0.160.420.21-0.24
-0.930.110.12-0.92-0.55-1.00.060.65-0.46-1.00.390.450.180.44-0.35-0.960.41-0.760.130.4-0.090.28-0.41-0.440.37
0.35-0.32-0.650.38-0.550.58-0.59-0.430.330.58-0.96-0.94-0.13-0.98-0.10.54-0.970.75-0.42-0.210.21-0.590.450.81-0.77
0.92-0.1-0.120.91-1.00.58-0.1-0.630.481.0-0.42-0.47-0.17-0.480.380.97-0.430.81-0.13-0.410.1-0.30.440.46-0.38
0.17-0.210.220.210.06-0.59-0.10.41-0.15-0.10.560.38-0.110.69-0.23-0.090.55-0.40.5-0.12-0.340.40.11-0.470.43
-0.47-0.150.17-0.460.65-0.43-0.630.41-0.07-0.630.310.230.060.42-0.22-0.60.31-0.380.370.09-0.120.250.1-0.540.34
0.59-0.120.120.56-0.460.330.48-0.15-0.070.48-0.26-0.340.33-0.230.40.6-0.280.450.21-0.180.52-0.130.11-0.22-0.14
0.92-0.1-0.120.91-1.00.581.0-0.1-0.630.48-0.42-0.47-0.17-0.480.380.97-0.430.81-0.13-0.410.1-0.30.440.46-0.38
-0.190.440.74-0.240.39-0.96-0.420.560.31-0.26-0.420.970.190.950.28-0.370.99-0.590.440.1-0.130.54-0.35-0.790.83
-0.320.570.73-0.370.45-0.94-0.470.380.23-0.34-0.470.970.120.890.32-0.450.97-0.610.30.2-0.150.5-0.49-0.720.79
0.07-0.040.240.050.18-0.13-0.17-0.110.060.33-0.170.190.120.130.160.070.19-0.090.320.040.750.19-0.13-0.370.23
-0.220.250.59-0.230.44-0.98-0.480.690.42-0.23-0.480.950.890.130.05-0.430.94-0.730.440.13-0.150.53-0.4-0.840.73
0.370.570.760.24-0.35-0.10.38-0.23-0.220.40.380.280.320.160.050.390.280.420.140.130.250.16-0.06-0.240.3
0.96-0.13-0.080.95-0.960.540.97-0.09-0.60.60.97-0.37-0.450.07-0.430.39-0.390.77-0.05-0.410.29-0.260.390.34-0.34
-0.210.410.75-0.260.41-0.97-0.430.550.31-0.28-0.430.990.970.190.940.28-0.39-0.60.470.17-0.150.62-0.39-0.780.82
0.65-0.04-0.180.62-0.760.750.81-0.4-0.380.450.81-0.59-0.61-0.09-0.730.420.77-0.6-0.17-0.440.1-0.40.640.58-0.42
0.11-0.220.470.10.13-0.42-0.130.50.370.21-0.130.440.30.320.440.14-0.050.47-0.170.05-0.090.740.19-0.550.7
-0.430.050.33-0.470.4-0.21-0.41-0.120.09-0.18-0.410.10.20.040.130.13-0.410.17-0.440.050.090.48-0.62-0.150.01
0.22-0.010.110.2-0.090.210.1-0.34-0.120.520.1-0.13-0.150.75-0.150.250.29-0.150.1-0.090.09-0.22-0.16-0.17-0.13
-0.13-0.150.53-0.160.28-0.59-0.30.40.25-0.13-0.30.540.50.190.530.16-0.260.62-0.40.740.48-0.22-0.28-0.440.54
0.4-0.38-0.250.42-0.410.450.440.110.10.110.44-0.35-0.49-0.13-0.4-0.060.39-0.390.640.19-0.62-0.16-0.280.35-0.09
0.16-0.23-0.710.21-0.440.810.46-0.47-0.54-0.220.46-0.79-0.72-0.37-0.84-0.240.34-0.780.58-0.55-0.15-0.17-0.440.35-0.73
-0.190.410.74-0.240.37-0.77-0.380.430.34-0.14-0.380.830.790.230.730.3-0.340.82-0.420.70.01-0.130.54-0.09-0.73
Click cells to compare fundamentals

ImmuPharma PLC Account Relationship Matchups

ImmuPharma PLC fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets5.8M10.9M6.0M4.0M2.7M2.6M
Other Current Liab175.4K110.7K158.8K200.0K768.5K806.9K
Total Current Liabilities531.9K1.3M1.6M1.5M1.7M1.4M
Total Stockholder Equity5.3M9.7M4.4M2.5M1.1M1.0M
Net Debt(1.3M)(5.2M)(1.6M)(667.7K)(208.5K)(218.9K)
Retained Earnings(40.2M)(46.0M)(56.6M)(61.1M)(64.1M)(60.9M)
Cash1.4M5.9M1.6M667.8K208.5K198.1K
Non Current Assets Total2.2M3.5M2.7M1.6M1.4M1.4M
Non Currrent Assets Other1.5M2.6M1.8M772.1K(1.0)(1.05)
Cash And Short Term Investments1.4M5.9M1.6M667.8K208.5K198.1K
Common Stock Total Equity13.3M13.9M16.7M25.0M28.8M30.2M
Common Stock Shares Outstanding153.5M200.2M251.2M302.9M362.0M380.1M
Liabilities And Stockholders Equity5.8M10.9M6.0M4.0M2.7M2.6M
Other Current Assets1.5M1.6M1.7M1.5M1.1M1.2M
Other Stockholder Equity23.9M23.8M27.2M28.8M29.3M30.8M
Total Liab531.9K1.3M1.6M1.5M1.7M1.7M
Total Current Assets3.6M7.4M3.3M2.3M1.3M1.3M
Common Stock16.7M25.0M28.5M29.0M29.8M31.3M
Short Long Term Debt Total26.8K641.8K700.0111.099.994.91
Property Plant And Equipment Net206.7K411.6K353.0K389.7K102.1K181.9K
Accounts Payable505.1K418.1K1.2M1.1M776.2K815.2K
Net Receivables709.1K481.9K1.1M166.3K685.7K950.6K
Property Plant And Equipment Gross206.7K411.6K1.1M1.3M192.3K280.6K
Accumulated Other Comprehensive Income5.0M6.8M8.7M9.3M6.0M6.3M
Short Term Debt26.8K641.8K700.0111.099.994.91
Intangible Assets479.0K484.0K477.6K473.9K447.6K477.8K
Property Plant Equipment164.7K206.7K411.6K353.0K405.9K426.2K
Current Deferred Revenue(175.4K)(201.0K)(427.7K)(380.1K)(437.1K)(458.9K)
Non Current Liabilities Total22.5K531.9K1.3M1.2M1.5M0.0
Net Tangible Assets5.2M9.6M3.9M2.5M2.8M5.2M
Short Long Term Debt98.3K26.8K641.8K700.0111.00.0
Capital Surpluse18.7M27.3M27.2M27.2M31.3M25.6M
Net Invested Capital5.3M10.3M4.4M2.5M1.1M1.0M
Net Working Capital3.0M6.2M1.8M887.6K(321.9K)(305.8K)
Capital Stock16.7M25.0M28.5M29.0M29.8M26.2M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in ImmuPharma Stock

Balance Sheet is a snapshot of the financial position of ImmuPharma PLC at a specified time, usually calculated after every quarter, six months, or one year. ImmuPharma PLC Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of ImmuPharma PLC and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which ImmuPharma currently owns. An asset can also be divided into two categories, current and non-current.